Company / Interest Expense
Vertex Pharmaceuticals Interest Expense History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$58.2M
FY2020
5-year range
-
FY2017-FY2020
Trend
-0.6%
vs FY2019
Sector context
#12 of 44
Health Care
What the data says
At $58M, Vertex Pharmaceuticals's interest expense ranks #33 of 44 in the Health Care sector. Improved from $72M to $58M over the past 2 years.
Based on SEC 10-K filings.
$58M in FY2020 with a 3-year CAGR of -5.7%.
Improved from $72M to $58M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#33 of 44 in Health CareTop 73% of 44This company $58.2M Sector average $291.0M
▼
-80.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -5.7%, indicating a declining trend.
- In FY2020, interest expense decreased 0.6% year-over-year.
- Ranks #12 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $58.2M | -0.6% |
| FY2019 | $58.5M | -19.3% |
| FY2018 | $72.5M | +4.6% |
| FY2017 | $69.3M | - |
| FY2016 | - | - |
As of FY2020 · SEC 10-K · Updated Mar 17, 2026